Shares of Rua Bioscience jumped +11.1% to NZD $0.04 after the New Zealand medicinal cannabis company announced it will bypass its third-party distributor and ship products directly from its Gisborne base. For a micro-cap still burning cash, the question is whether owning the last mile of delivery can bend its economics toward profitability.
Five New Products Give the Direct Model Something to Sell. The timing follows regulatory approval for five new products, broadening Rua's range just as it takes control of domestic distribution.
Rua's New Zealand sales grew significantly in FY26 , but a wider catalogue means nothing if it can't be placed efficiently — the direct model is management's bet that it can.
Margins Matter More Than Revenue at This Scale. In the first half of FY26, Rua reported sales of NZ$1.33 million, up 92% from $694,000 in the prior period. Yet net loss before tax barely improved, falling to $1.79 million versus $1.80 million a year earlier.
Previously, Rua distributed nationally via CDC Pharmaceuticals — cutting that intermediary should let the company keep a larger slice of each sale. CEO Paul Naske was explicit: "The move will improve our margins." For a company that lost NZ$3.36 million pre-tax in FY26, with only modest improvement even after excluding one-off impairments , every percentage point of gross margin recaptured counts.
The Domestic Market Is Real but Small. New Zealand's medicinal cannabis market is estimated at around $60 million and still growing, with telehealth clinics playing an increasingly central role. Rua is one of several licensed players chasing that pool. Even aggressive market-share gains would generate only single-digit millions — not enough alone to cover current losses.
Export Revenue Is the Bigger Swing Factor. In July 2026, Rua signed its largest-ever export deal — a UK distribution agreement expected to generate NZ$10 million over two years , dwarfing domestic sales. Meanwhile, the board recently secured a convertible-note facility, flagging a going-concern note in its preliminary financials — a reminder that the company still needs outside capital to operate.
The direct-distribution pivot is sound cost hygiene, but at $0.04 a share and cash still flowing out, investors are buying a thesis, not a turnaround — yet.